Quarterly report pursuant to Section 13 or 15(d)

Summary of Significant Accounting Policies (Details)

v3.22.2.2
Summary of Significant Accounting Policies (Details) - USD ($)
$ in Thousands
 3 Months Ended 12 Months Ended
Aug. 31, 2022
Aug. 31, 2021
 [1]
May 31, 2022
Feb. 28, 2022
Summary Of Significant Accounting Policies [Line Items]        
Net loss $ 20,991 $ 45,337    
Accumulated deficit 782,857   $ 766,131 $ 782,900
Charge to APIC due to warrant modification 4,200      
Change of fair value of liability-classified equity instrument upon reclassification $ 8,601      
Bulk Drug Substance        
Summary Of Significant Accounting Policies [Line Items]        
Shelf life 4 years   4 years  
[1] See Note 2, Summary of Significant Accounting Policies.